ERBB3 and cancer: The result was unexpected because numerous studies in HNSCC and other cancer cell lines generally indicated that co-targeting ErbB3 with EGFR or other pathways, chemotherapy, or radiotherapy, was required to yield a significant benefit from ErbB3 inhibition26,28–32.